LibbyP. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol2005; 46: 1225–1228.
2.
Gregson JM, Freitag DF, Surendran P, et al. Genetic invalidation of Lp-PLA2 as a therapeutic target: large-scale study of five functional Lp-PLA2 lowering alleles. Eur J Prev Cardiol. 2017; 24: 492–504.
3.
O’DonoghueMLBraunwaldEWhiteHD. SOLID-TIMI 52 Investigators. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA2014; 312: 1006–1015.
4.
WhiteHDHeldCStewartR. The STABILITY Investigators. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med2014; 370: 1702–1711.
5.
ZalewskiAMacpheeC. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol2005; 25: 923–931.
SerruysPWGarcia-GarciaHMBuszmanP. Integrated Biomarker and Imaging Study-2 Investigators. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation2008; 118: 1172–1182.
8.
ThompsonAGaoPOrfeiL. Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet2010; 375: 1536–1544.
9.
FerenceBARobinsonJGBrookRD. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med2016; 375: 2144–2153.
10.
VoightBFPelosoGMOrho-MelanderM. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet2012; 380: 572–580.
11.
NordestgaardBG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res2016; 118: 547–563.
12.
NordestgaardBGLangstedA. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res2016; 57: 1953–1975.
13.
SchwartzGGOlssonAGAbtM. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med2012; 367: 2089–2099.
14.
TardifJCRheaumeELemieux PerreaultLP. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet2015; 8: 372–382.
